Page 1

idorsia Media Release June 28 , 2021 Ad hoc announcement pursuant to Art . 53 LR Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction Idorsia to host an investor webcast to discuss the Phase 3 study today at 14 : 30hrs CEST ● Allschwil , Switzerland - June 28 , 2021 Idorsia Ltd ( SIX : IDIA ) today announced the initiation of the Phase 3 registration study " SOS - AMI " to evaluate the efficacy and safety of self - administered subcutaneous selatogrel , Idorsia's P2Y12 receptor antagonist , in suspected acute myocardial infarction ( AMI ) . An AMI , or heart attack , is a life - threatening condition that occurs when blood flow to the heart muscle ( myocardium ) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels . An AMI requires immediate treatment , as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes . According to the US Centers for Disease Control and Prevention , each year more than 800,000 persons living in the US will suffer a heart attack . [ 1 ] Although the management of AMI has improved in recent decades , morbidity and mortality associated with AMI remain high . The majority of deaths occur outside the hospital . [ 2,3 ] Early action is crucial for survival and to preserve heart muscle . Besides aspirin , there are no treatment options currently available for the critical time from onset of AMI symptoms to first medical contact . The development of selatogrel in an autoinjector aims to fulfill this medical gap : upon symptoms suggestive of a heart attack , patients would self - inject selatogrel as early as possible and immediately call for emergency medical help . Martine Clozel , MD and Chief Scientific Officer at Idorsia , commented : " From the moment that symptoms start , the clock is ticking . Thrombus formation is progressing , and ischemia is rapidly causing irreversible damage to the heart . In the initial stages of thrombus formation , platelet aggregation dominates - a process in which the platelet P2Y12 receptor plays a key role . If left untreated , the thrombus will become fibrin rich , at which point platelets have a more limited role in thrombus formation . This suggests that a fast - acting P2Y12 receptor antagonist could cut short the thrombus formation in the initial stages of thrombus formation . Our drug discovery team has created a compound with unique properties which might fill this important therapeutic gap . " Dr Deepak L. Bhatt , MD , MPH , Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital , Professor of Medicine at Harvard Medical School , and Chair of the Steering Committee for SOS - AMI , commented : " P2Y12 receptor antagonists have been used in the treatment of millions of patients globally , and their safety and efficacy profiles are well established . Despite the success of chronic treatment with this class and other effective interventions , patients are still suffering recurrent heart attacks . The idea for patients to self - inject early in the onset of symptoms is truly innovative . The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class . "